Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMG1015 in Healthy Volunteers
NCT05022771Phase 1Completed
- Sponsor
- Pulmongene (Hong Kong) Co., Ltd.
- Start
- Oct 2021
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PMG1015 in idiopathic pulmonary fibrosis (IPF) (7 cohorts), sponsored by Pulmongene (Hong Kong) Co., Ltd. Primary endpoints: Treatment-Emergent Adverse Events, Serious Adverse Events and 5 more. Started Oct 2021; status: completed.
02
Drugs
PMG1015
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05022771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05022771.